Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598404 | 0.88 | CYP2C19 (0.54) | CYP2C19FGFR1SRCFGFR2FGFR4 | |
| SCHEMBL1547038 | 0.85 | KMT2A (0.56) | CYP2C19PTGDR2FFAR4FFAR1KMT2A | |
| SCHEMBL2391279 | 0.85 | CYP2C19 (0.48) | CYP2C19KMT2AACLY | |
| SCHEMBL3540535 | 0.84 | SUCNR1 (0.56) | CYP2C19PTGDR2FFAR4FFAR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL27396597 | 0.84 | KMT2A (0.55) | CYP2C19PTGDR2FFAR4FFAR1KMT2A | |
| SCHEMBL7311559 | 0.84 | BCAT2 (0.50) | CYP2C19PTGS1KMT2AACLYDPP4 | |
| SCHEMBL2391344 | 0.83 | FFAR1 (0.46) | CYP2C19FFAR4FFAR1SLC6A3KMT2A | |
| SCHEMBL2392196 | 0.83 | PTGDR2 (0.46) | CYP2C19PTGDR2FFAR4FFAR1SLC6A4 | |
| SCHEMBL2395091 | 0.83 | CYP2C19 (0.49) | CYP2C19FFAR4FFAR1ACLYNPC1 | |
| SCHEMBL2393760 | 0.82 | CHRM1 (0.56) | CYP2C19ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-1567502-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | Wyeth (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050631-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CYP2C19 240/4885FGFR1 294/4885SRC 2996/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CYP2C19 240/4885FGFR1 294/4885SRC 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.